# KO-MEN-017: HCP commentary report

> 34 verified statements (19 from speakers with a confirmed clinical role) from 7 commentary sources · 4 findings · updated Oct 19, 2026

## Report

- Trial: Phase 3 Randomized, Double-blind, Placebo-controlled Studies Assessing Ziftomenib in Combination With Either Standard of Care Nonintensive (Venetoclax+Azacitidine) or Intensive (7+3) Therapy in Patients With Untreated NPM1 Mutated or KMT2A Rearranged Acute Myeloid Leukemia
- NCT ID: NCT07007312
- Registry: https://clinicaltrials.gov/study/NCT07007312
- Sponsor: Kura Oncology, Inc.
- Phase: Phase 3
- Status: Recruiting
- Drugs: ziftomenib, venetoclax, azacitidine, daunorubicin, cytarabine
- Indications: Acute myeloid leukemia
- Version: v1.0.0, edition 1
- Accepted: 2026-10-19
- Last checked: 2026-10-19
- Release hash: 76bdeac3e5d20ffeb8265539f86f7e7218ffed00d5e3e7d200a3901eff0b4760

## Counts

- HCP commentary sources screened: 8
- Sources cited by verified statements: 7
- Verified statements: 34
- From speakers with a confirmed clinical role: 19
- Findings: 4
- People found in screened sources: 7
- People identity-verified: 5
- Voices cited: 7

Counts describe the retained sources. They do not estimate how many HCPs hold a view.

## Abstract

KO-MEN-017 asks whether adding ziftomenib to intensive or nonintensive treatment improves outcomes in untreated NPM1-mutated or KMT2A-rearranged AML. Clinicians in the sources reviewed for this edition make the intensive-treatment rationale conditional on patient selection, while leaving triplet selection open. Their enthusiasm for frontline combinations accompanies scrutiny of differentiation-syndrome comparisons and treatment scheduling. Whether outcomes improve and how triplets should be dosed remain unresolved.

## Open Medical Affairs question

What evidence would justify moving from encouraging response depth to confidence in improved frontline outcomes?

Raised by the leading finding. The report shows what clinicians said and the sources behind it; it does not settle the question.

## Findings (titles)

- F1. Frontline enthusiasm rests on early response signals, not established outcome improvement
- F2. The intensive-treatment rationale depends on relapse risk and the earlier cohort's selection
- F3. Favorable tolerability reports leave differentiation-syndrome comparisons and scheduling effects unresolved
- F4. Triplet selection, dosing and a less-intensive bridge to transplant remain open questions

## What sits behind each finding

Counts describe what the report retained, not how many clinicians hold a view. A statement can support more than one finding.

| Finding | Statements | Passages | Sources | Named voices | Counterview | Limitations |
| --- | ---: | ---: | ---: | ---: | --- | ---: |
| F1 | 10 | 11 | 4 | 4 | none recorded | 3 |
| F2 | 5 | 2 | 1 | 1 | none recorded | 4 |
| F3 | 6 | 3 | 3 | 3 | none recorded | 3 |
| F4 | 3 | 3 | 1 | 1 | none recorded | 3 |

### What the statements are

| Finding | Views | Questions and uncertainty | Clinical experience | Comparisons | Restated results and context | Passages supporting | Passages giving context | Sources by kind | Feeds the Medical Affairs question |
| --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | --- | --- |
| F1 | 4 | 1 | 3 | 2 | 0 | 12 | 4 | 1 post or article, 3 podcasts and video | yes |
| F2 | 1 | 2 | 1 | 1 | 0 | 5 | 3 | 1 podcast or video | yes |
| F3 | 2 | 1 | 2 | 1 | 0 | 6 | 3 | 3 podcasts and video | yes |
| F4 | 0 | 3 | 0 | 0 | 0 | 3 | 3 | 1 podcast or video | yes |

### Trial dimensions

- Primary endpoint: Nonintensive Therapy Study: (Primary Endpoint for all countries): Overall survival (OS): F1 (1 shared claims)
- Primary endpoint: Nonintensive Therapy Study: (Dual Primary Endpoint for US & US reference countries only): Complete remission (CR): F1 (1 shared claims)
- Primary endpoint: Intensive Therapy Study: (Primary Endpoint for all countries): Event-free survival (EFS): no finding draws on it directly
- Primary endpoint: Intensive Therapy Study: (Dual Primary Endpoint for US & US reference countries only): Complete remission (CR) with bone marrow (BM) measurable residual disease (MRD) negativity in NPM1-m patients: F3 (1 shared claims)
- Secondary endpoints: F1 (4 shared claims), F3 (6 shared claims)
- Population and setting: F1 (1 shared claims), F2 (2 shared claims), F4 (3 shared claims)
- The comparison: F1 (1 shared claims)
- Safety and tolerability: F1 (2 shared claims), F2 (1 shared claims), F3 (6 shared claims)
- Design and conduct: F1 (3 shared claims)

## Sample findings

Paraphrased; the full report links each statement to its source.

## What's inside

| Section | Items | Access |
| --- | ---: | --- |
| Findings with interpretation, counterviews and limits | 4 | Titles free |
| Detailed analysis | 5 sections | Paid |
| Verified statements with short source quotes and links | 34 | Paid |
| Trial aspects mapped | 12 | Free |
| Sources with links | 7 | Counts free |
| Speaker attribution for cited voices | 7 | Paid |

## Trial aspects

11 discussed · 1 no commentary found · 0 assessment incomplete.

| Aspect | Coverage | Statements | Sources |
| --- | --- | ---: | ---: |
| Primary endpoint: Nonintensive Therapy Study: (Primary Endpoint for all countries): Overall survival (OS) | discussed | 1 | 1 |
| Primary endpoint: Nonintensive Therapy Study: (Dual Primary Endpoint for US & US reference countries only): Complete remission (CR) | discussed | 1 | 1 |
| Primary endpoint: Intensive Therapy Study: (Primary Endpoint for all countries): Event-free survival (EFS) | no commentary found | 0 | 0 |
| Primary endpoint: Intensive Therapy Study: (Dual Primary Endpoint for US & US reference countries only): Complete remission (CR) with bone marrow (BM) measurable residual disease (MRD) negativity in NPM1-m patients | discussed | 1 | 1 |
| Secondary endpoints | discussed | 9 | 4 |
| Population and setting | discussed | 10 | 3 |
| The comparison | discussed | 2 | 2 |
| Safety and tolerability | discussed | 8 | 4 |
| Design and conduct | discussed | 5 | 3 |
| Early response signals and the need to demonstrate outcome improvement | discussed | 14 | 4 |
| Dose sequencing and explanations for differentiation-syndrome differences | discussed | 6 | 2 |
| Younger-fit triplets and a less-intensive bridge to transplant | discussed | 3 | 1 |

An aspect marked incomplete is a question the public commentary did not let us answer. We show it rather than hide it.

## Sources

| Channel | Screened | Cited |
| --- | ---: | ---: |
| X threads | 5 | 4 |
| YouTube | 3 | 3 |

- Screened window: 2025-02-11 to 2026-10-14
- Cited window: 2025-02-11 to 2026-10-14
- Retrieved: 2026-10-18

Screened sources were retrieved for this trial. Cited sources back at least one verified statement and include primary sources used for context.

## The trial

From ClinicalTrials.gov.

- Title: Phase 3 Randomized, Double-blind, Placebo-controlled Studies Assessing Ziftomenib in Combination With Either Standard of Care Nonintensive (Venetoclax+Azacitidine) or Intensive (7+3) Therapy in Patients With Untreated NPM1 Mutated or KMT2A Rearranged Acute Myeloid Leukemia
- Registry: NCT07007312 (https://clinicaltrials.gov/study/NCT07007312)
- Study IDs: KO-MEN-017 · 2025-521314-25-00
- Sponsor: Kura Oncology, Inc.
- Design: Phase 3 · interventional, randomized, parallel, phase3
- Status: Recruiting
- Enrollment: 1,300 (estimated)
- Start: 2025-09-26 (actual)
- Primary completion: 2031-11 (estimated)
- Primary endpoint: Nonintensive Therapy Study: (Primary Endpoint for all countries): Overall survival (OS) (Defined as the time from randomization to date of death from any cause, assessed up to 36 months after last patient inclusion)
- Primary endpoint: Nonintensive Therapy Study: (Dual Primary Endpoint for US & US reference countries only): Complete remission (CR) (Assessed up to 36 months after last patient inclusion)
- Primary endpoint: Intensive Therapy Study: (Primary Endpoint for all countries): Event-free survival (EFS) (Defined as the time from randomization to treatment failure, hematologic relapse following CR, or death from any cause, whichever comes first, assessed up to 36 months after last patient inclusion)
- Primary endpoint: Intensive Therapy Study: (Dual Primary Endpoint for US & US reference countries only): Complete remission (CR) with bone marrow (BM) measurable residual disease (MRD) negativity in NPM1-m patients (Assessed up to 36 months after last patient inclusion)
- Intervention: Ziftomenib (drug)
- Intervention: Placebo (drug)
- Intervention: Venetoclax (drug)
- Intervention: Azacitidine (AZA) (drug)
- Intervention: Daunorubicin (drug)
- Intervention: Cytarabine (Ara-C) (drug)

## Scope and limits

This report does not judge efficacy, estimate HCP prevalence or consensus or give treatment advice.

- Discussion that does not name the trial may be missing from this edition.
- Some clinician views in the sources used in this report are not yet captured as evidence in this edition; the next refresh takes them up.
- Some passages in the sources used in this report were not fully assessed for clinician views, so a view there may be missing from this edition.
- 16 statements in the sources reviewed for this edition discuss other treatment settings or topics unrelated to this trial's question and are not included.
- Further source limits: discussion that describes the trial without naming it may be incomplete; some discussion that describes the trial without naming it may be missing; sources about other trials are not included.
- The discussion comes from the sources reviewed for this edition and cannot establish how common these views are among HCPs. Several posts report presentations rather than independent clinical assessments.
- No protocol or results publication for the exact KOMET-017 trial was identified. The clinical observations discussed here must not be treated as randomized KOMET-017 findings.
- The earlier response and safety accounts often omit denominators, follow-up duration or numerical rates. Zeidan's 40-patient response figures cannot be assigned to a specific frontline or relapsed/refractory cohort from the passage.
- Speaker descriptions differ in regimen detail: Zeidan named azacitidine/venetoclax, whereas Zeidner's older/unfit KOMET-017 comparison named azacitidine without venetoclax. These descriptions do not establish a clinical disagreement.
- The differentiation-syndrome comparisons concern different inhibitors, schedules and treatment settings. They do not establish a head-to-head safety advantage or a causal effect of starting treatment later.

How reports are built and checked: https://www.erudio.com/methods

## Editions and corrections

- v1.0.0, accepted 2026-10-19: current edition, corrected 2026-10-19
  - Correction 2026-10-19: Report description rewritten to say where clinicians' views stand, not only what they discuss
  - Correction 2026-10-19: taxonomy mapping corrected

Last checked for new commentary 2026-10-19. Versions follow semver: a new or changed finding is a minor version, more evidence without a material change is a patch.

## Offer

- Size: Focused (34 verified statements)
- Current edition: $750. A purchase starts a check for new commentary and any newer edition follows at no charge
- 3 months of weekly updates: $1,300
- 6 months of weekly updates: $1,900
- 12 months of weekly updates: $2,600
- Optional identity linkages (12-month updates only, product updates-12-identities; speakers are named and described in every report): NPI and other verified IDs at $15 per identity-verified person in the edition at purchase (5 now), at most $750; people verified later in the term at no charge
- Pricing: https://www.erudio.com/pricing
- Buy now (card, through Stripe): https://www.erudio.com/reports/ko-men-017-nct07007312
- Agents: POST https://www.erudio.com/api/orders with {"report": "ko-men-017-nct07007312", "product": "edition" | "updates-3" | "updates-6" | "updates-12" | "updates-12-identities", "buyer_email": "...", "licence_key": "<your key, if you hold one>"}; it returns a payment link for your user (and a pay_url your own MPP or x402 payment client can pay over HTTP 402, when offered), and once paid the status_url returns your license key. Send the same key with every later order so all reports sit on one key. The buyer gets their account key by email, which reads every report bought with their address; recover_key (POST https://www.erudio.com/api/keys/recover) sends it again
- Talk to Audun Utengen and Tom Lee (invoice, PO, questions): https://www.erudio.com/contact?report=ko-men-017-07007312

## Cite

Erudio Health. KO-MEN-017 (NCT07007312): HCP commentary report. Edition 1, v1.0.0. Accepted Oct 19, 2026. https://www.erudio.com/reports/ko-men-017-nct07007312

## Machine access

- JSON: https://www.erudio.com/reports/ko-men-017-nct07007312.json
- Markdown: https://www.erudio.com/reports/ko-men-017-nct07007312.md
- MCP: https://mcp.erudio.com/mcp, tool `get_report_card` with `{"slug": "ko-men-017-07007312"}`